ASCO 2015 Highlights

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Page 215 of 329